Kenneth Lim, MD, PhD
Assistant Professor of Medicine
Attending Physician | Indiana University Health
Principal Investigator | The Lim Laboratory | Division of Nephrology
Affiliate Faculty, Division of Cardiovascular Medicine
Member, Krannert Cardiovascular Research Center (KCRC)
Member, Indiana Center for Musculoskeletal Health (ICMH)
- kjlim@iu.edu
- Address
-
R2 202
NEPH
IN
Indianapolis, IN - PubMed:
-
Bio
Dr. Ken Lim, MD, PhD, MPhil, FASN, FAHA, FRCP, is an American Physician-Scientist and Nephrologist and Entrepreneur. The mission of his work is to create potential solutions to challenging issues of humanitarian need in healthcare and human suffering through innovative research, academic entrepreneurship and the delivery of medical care beyond borders. Prior to joining the faculty at IUSM in 2020, he spent ~10 years at Harvard Medical School and affiliated major teaching hospitals. From 2018 – 2020, he was appointed Attending Physician at The Massachusetts General Hospital and a Faculty Member at Harvard Medical School. He is a graduate of The University of Cambridge (Christ’s College) and The University of Warwick in England.
Dr. Lim is a clinical trialist and translational scientist with a subspecialty interest in cardionephrology. He has a special interest in the development of cardiovascular functional endpoints for regulatory efficacy trials in nephrology, solutions to methodologic challenges in cardiorenal clinical trial design and in peptidomimetics. He leads a research group at IUSM that focuses on the development and delivery of definitive clinical trials in patients with kidney failure and cardiovascular complications, and the development of advanced peptide-based therapeutics. He founded the first Cardiopulmonary Exercise Testing (CPET) laboratory dedicated to the study of patients with kidney disease in the United States. He continues to be engaged in starting new companies at the forefront of innovation to bring sustainable impact, and translational strategies for taking biological discoveries into early phase exploratory trials.
He is the recipient of the Genzyme-Sanofi Fellowship in Nephrology, ASN Carl W. Gottschalk Research Scholar award, the Young Physician–Scientist Award by the American Society of Clinical Investigation (ASCI), full membership of the Sigma Xi Scientific Research Honor Society, and the Indianapolis Business Journal (IBJ) Forty Under 40 Award among others. He has been named Fellow of the American Society of Nephrology (FASN), Fellow of the American Heart Association (FAHA) and most recently, he was induced Fellow of the Royal College of Physicians (FRCP). He has served as strategic advisor or consultant to leaders from diverse sectors, he has held offices of leadership on numerous boards and has appeared on various television and media programs.
| Year | Degree | Institution |
|---|---|---|
| 2018 | Fellowship | Massachusetts General Hospital |
| 2018 | Fellowship | Harvard Medical School |
| 2018 | Fellowship | Brigham and Women's Hospital |
| 2018 | M.Sc. | University of Cambridge |
| 2015 | Residency | Oregon Health & Science University |
| 2012 | PhD | University of Warwick |
| 2008 | MD | University of Warwick |
| 2004 | BSC | Coventry University |
The mission of The Lim Laboratory is to help develop and deliver definitive trials in the area of cardiovascular disease in patients with kidney failure, and to be an incubator for the development of advanced therapeutics. We integrate multidisciplinary approaches at the interface of translational and clinical research for improved patient care.
Our primary R&D platform focuses on therapeutic strategies for targeting cardiovascular disease in kidney failure, a current global health crisis. This capitalizes on our platform technologies, and translational & commercialization strategies in our group that accelerate entry of biological discoveries into early phase trials. We have an emphasis on multidisciplinary collaborations with projects that draw from an international talent pool. The process of innovation leverages on our relationships and networks with industry and beyond.
One of the major platform technologies in our clinical research lab focuses on the use of state-of-the-art Cardiopulmonary Exercise Testing (CPET) technology, a robust and powerful technology that can accurately and reproducibly assess cardiovascular functional capacity. We are at the forefront of efforts to introduce CPET technology into the field of nephrology. The potential exists for CPET indices such as VO2Peak to be used as a new endpoint for cardiovascular trials in nephrology which can help overcome current challenges in cardio-renal trials methodologies. The technology has the potential to help move the cardio-renal field forward.
Our wet lab specializes in translational research that focuses on the discovery and development of peptide therapeutics for cardiac disorders in kidney failure and beyond. We lead several exciting translational research studies using multidisciplinary approaches in cell and molecular biology, bioengineering and human tissue research. We take the approach of integrating our translational wet lab and clinical research efforts, and this stimulates multi-disciplinary collaboration on projects that support each other.
Cardio-Nephrology
Cardiorenal Syndrome
Chronic Kidney Disease (CKD)
Hemodialysis
End-Stage Kidney Disease (ESKD)
Disaster Medicine/Nephrology